Your browser is no longer supported. Please, upgrade your browser.
VYGR [NASD]
Voyager Therapeutics, Inc.
Index- P/E3.06 EPS (ttm)1.03 Insider Own1.80% Shs Outstand37.50M Perf Week-5.67%
Market Cap126.08M Forward P/E- EPS next Y-2.73 Insider Trans-2.89% Shs Float32.44M Perf Month-28.83%
Income39.40M PEG- EPS next Q-0.71 Inst Own69.90% Short Float2.70% Perf Quarter-41.91%
Sales159.60M P/S0.79 EPS this Y181.00% Inst Trans-0.63% Short Ratio1.74 Perf Half Y-63.64%
Book/sh3.63 P/B0.87 EPS next Y-4.90% ROA14.80% Target Price- Perf Year-73.78%
Cash/sh4.05 P/C0.78 EPS next 5Y- ROE29.50% 52W Range3.10 - 12.70 Perf YTD-55.80%
Dividend- P/FCF- EPS past 5Y21.60% ROI17.70% 52W High-75.12% Beta1.00
Dividend %- Quick Ratio7.10 Sales past 5Y58.10% Gross Margin- 52W Low1.94% ATR0.20
Employees177 Current Ratio7.10 Sales Q/Q-64.10% Oper. Margin16.40% RSI (14)27.16 Volatility4.83% 5.59%
OptionableYes Debt/Eq0.00 EPS Q/Q12.10% Profit Margin24.70% Rel Volume0.59 Prev Close3.12
ShortableYes LT Debt/Eq0.00 EarningsMay 25 AMC Payout0.00% Avg Volume502.31K Price3.16
Recom2.60 SMA20-15.85% SMA50-23.84% SMA200-52.52% Volume363,019 Change1.28%
Feb-26-21Downgrade Robert W. Baird Outperform → Neutral $18 → $6
Feb-03-21Downgrade Wedbush Outperform → Neutral $6
Feb-03-21Downgrade BTIG Research Buy → Neutral
Dec-24-20Downgrade Cantor Fitzgerald Overweight → Neutral $15 → $10
Dec-23-20Downgrade Raymond James Outperform → Mkt Perform
Nov-11-20Downgrade Oppenheimer Outperform → Perform
Nov-10-20Downgrade Wells Fargo Overweight → Equal Weight $10
Nov-10-20Downgrade Raymond James Strong Buy → Outperform $28 → $17
Mar-19-20Initiated The Benchmark Company Buy $18
Feb-06-20Initiated Oppenheimer Outperform
Nov-15-18Upgrade Raymond James Outperform → Strong Buy
Sep-10-18Resumed BTIG Research Buy $32
Sep-10-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-04-18Initiated H.C. Wainwright Buy $30
Mar-12-18Downgrade Wedbush Outperform → Neutral $29
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Feb-02-18Initiated Morgan Stanley Overweight
Nov-28-17Resumed Piper Jaffray Overweight $28
Oct-31-17Initiated Robert W. Baird Outperform $31
Oct-27-17Initiated Canaccord Genuity Buy $35
Jun-30-21 07:58AM  
May-19-21 04:01PM  
May-12-21 10:20AM  
07:30AM  
May-11-21 07:30AM  
May-10-21 08:45AM  
07:30AM  
Apr-29-21 10:50AM  
Apr-28-21 12:33PM  
08:00AM  
Apr-27-21 10:10AM  
08:05AM  
Apr-26-21 09:32AM  
08:00AM  
Apr-20-21 10:51AM  
Mar-24-21 10:08AM  
10:00AM  
02:10AM  
Mar-23-21 06:45PM  
06:05PM  
01:00PM  
08:30AM  
Mar-22-21 01:00PM  
08:30AM  
Mar-21-21 08:06PM  
02:20PM  
Mar-19-21 10:29AM  
Mar-18-21 06:14PM  
05:25PM  
10:26AM  
10:00AM  
12:50AM  
Mar-17-21 04:17PM  
02:20PM  
11:00AM  
10:25AM  
Mar-16-21 08:45PM  
11:00AM  
Mar-15-21 12:40PM  
11:00AM  
Mar-14-21 10:54PM  
Mar-12-21 06:00PM  
05:45PM  
02:34PM  
04:05AM  
Mar-11-21 11:45AM  
Mar-10-21 09:56PM  
Mar-09-21 04:40PM  
11:00AM  
10:00AM  
Mar-08-21 09:15PM  
12:30PM  
Mar-07-21 12:44PM  
Mar-06-21 11:30AM  
Mar-05-21 11:55AM  
Mar-03-21 04:12PM  
03:40PM  
01:10AM  
Mar-02-21 12:55PM  
11:00AM  
Mar-01-21 12:20AM  
Feb-28-21 02:41AM  
Feb-27-21 09:00AM  
Feb-26-21 10:04AM  
Feb-25-21 10:14PM  
04:01PM  
02:30PM  
01:19PM  
Feb-24-21 02:04PM  
11:45AM  
Feb-23-21 07:45PM  
11:50AM  
11:20AM  
Feb-22-21 03:16PM  
12:30PM  
12:06PM  
10:48AM  
Feb-20-21 05:00PM  
11:40AM  
Feb-19-21 01:00PM  
12:20AM  
Feb-18-21 11:18PM  
07:10PM  
04:01PM  
Feb-17-21 04:27PM  
10:00AM  
Feb-16-21 04:05PM  
11:04AM  
Feb-15-21 09:07PM  
03:56PM  
01:00PM  
Feb-13-21 03:50PM  
01:20PM  
01:10PM  
Feb-12-21 12:00PM  
Feb-10-21 11:40PM  
04:28PM  
11:00AM  
09:20AM  
08:00AM  
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Khwaja OmarSee remarksMay 21Sale4.033,51614,169120,509May 25 04:31 PM
Turenne AndrePresident & CEOFeb 11Sale7.557,97760,226148,375Feb 16 04:11 PM
Dorval AllisonChief Financial OfficerFeb 11Sale7.553,18624,05445,894Feb 16 04:10 PM
Hesslein Robert W.Senior VP & General CounselFeb 11Sale7.553,18624,05449,348Feb 16 04:08 PM
Khwaja OmarSee remarksFeb 11Sale7.553,47526,23653,025Feb 16 04:06 PM
Turenne AndrePresident & CEOJan 12Sale8.6210,44390,019156,352Jan 14 05:59 PM
Dorval AllisonChief Financial OfficerJan 12Sale8.622,94225,36049,080Jan 14 05:57 PM